This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Aug;63(8):1208-9.

doi: 10.1136/gutjnl-2013-306221. Epub 2014 Jan 7.

HBsAg seroclearance with NUCs: rare but important

Markus Cornberg¹, Christoph Höner Zu Siederdissen¹

Affiliations

PMID: 24398879
DOI: 10.1136/gutjnl-2013-306221

Comment

HBsAg seroclearance with NUCs: rare but important

Markus Cornberg et al. Gut. 2014 Aug.

. 2014 Aug;63(8):1208-9.

doi: 10.1136/gutjnl-2013-306221. Epub 2014 Jan 7.

Authors

Markus Cornberg¹, Christoph Höner Zu Siederdissen¹

Affiliation

¹ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

PMID: 24398879
DOI: 10.1136/gutjnl-2013-306221

No abstract available

Keywords: HEPATITIS B.

PubMed Disclaimer

Comment on

HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. Kim GA, et al. Gut. 2014 Aug;63(8):1325-32. doi: 10.1136/gutjnl-2013-305517. Epub 2013 Oct 25. Gut. 2014. PMID: 24162593

Similar articles

[Is HBsAg loss an ideal end-point of oral antiviral therapy in chronic hepatitis B patients?].
Kang K, Kim JH. Kang K, et al. Korean J Gastroenterol. 2014 May;63(5):329-32. doi: 10.4166/kjg.2014.63.5.329. Korean J Gastroenterol. 2014. PMID: 25007428 Korean. No abstract available.
HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. Kim GA, et al. Gut. 2014 Aug;63(8):1325-32. doi: 10.1136/gutjnl-2013-305517. Epub 2013 Oct 25. Gut. 2014. PMID: 24162593
HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma.
Kim JH, Lee YS, Lee HJ, Yoon E, Jung YK, Jong ES, Lee BJ, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. Kim JH, et al. J Clin Gastroenterol. 2011 Jan;45(1):64-8. doi: 10.1097/MCG.0b013e3181dd558c. J Clin Gastroenterol. 2011. PMID: 20535028
Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).
Grossi G, Viganò M, Loglio A, Lampertico P. Grossi G, et al. Liver Int. 2017 Jan;37 Suppl 1:45-51. doi: 10.1111/liv.13291. Liver Int. 2017. PMID: 28052621 Review.
Hepatitis B surface antigen seroclearance during chronic HBV infection.
Chu CM, Liaw YF. Chu CM, et al. Antivir Ther. 2010;15(2):133-43. doi: 10.3851/IMP1497. Antivir Ther. 2010. PMID: 20386068 Review.

See all similar articles

Cited by

T cell--associated immunoregulation and antiviral effect of oxymatrine in hydrodynamic injection HBV mouse model.
Sang X, Wang R, Han Y, Zhang C, Shen H, Yang Z, Xiong Y, Liu H, Liu S, Li R, Yang R, Wang J, Wang X, Bai Z, Xiao X. Sang X, et al. Acta Pharm Sin B. 2017 May;7(3):311-318. doi: 10.1016/j.apsb.2017.02.005. Epub 2017 May 2. Acta Pharm Sin B. 2017. PMID: 28540167 Free PMC article.
PgRNA kinetics predict HBsAg reduction in pregnant chronic hepatitis B carriers after treatment cessation.
Wang CR, Liu XQ, Li H, Zhang Q, Zhong GC, Tang Q, Chang Y, Wang JS, Duan YQ, Hu P. Wang CR, et al. Front Cell Infect Microbiol. 2022 Dec 12;12:1055774. doi: 10.3389/fcimb.2022.1055774. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36579348 Free PMC article.
Steatosis and Interferon Associated with HBsAg Immune Control in Chronic Hepatitis B: A Real-World Propensity Score-Matched Study.
Xu Q, Chen J, Yao B, Zhang X, Han Y. Xu Q, et al. Biomedicines. 2025 Jun 24;13(7):1538. doi: 10.3390/biomedicines13071538. Biomedicines. 2025. PMID: 40722612 Free PMC article.
Immunological cure of HBV infection.
Lang J, Neumann-Haefelin C, Thimme R. Lang J, et al. Hepatol Int. 2019 Mar;13(2):113-124. doi: 10.1007/s12072-018-9912-8. Epub 2019 Jan 2. Hepatol Int. 2019. PMID: 30600480 Review.
Management of HBV and HBV/HDV-Associated Liver Cirrhosis.
Höner Zu Siederdissen C, Cornberg M. Höner Zu Siederdissen C, et al. Visc Med. 2016 Apr;32(2):86-94. doi: 10.1159/000445518. Epub 2016 Apr 12. Visc Med. 2016. PMID: 27413725 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information